SU-G-BRC-07: Evaluation of AAA Focal Spot Size for SRS Planning Using End-To-End Dosimetric Data.

PURPOSE: To use end-to-end dosimetric measurements with Gafchromic film to evaluate the effects of focal spot size parameter for small-field dose calculations using AAA for SRS lesions.

METHODS: A total of 13 plans, corresponding to 7 patients previously treated with cranial SRS, were analyzed in this study (target volume range:[0.67cc,13.9cc]). The plans included DCA delivery (4 plans total) and VMAT delivery (9 plans total). All plans were mapped to a solid water phantom (15 cm thickness; isocenter and film plane at 7.5 depth). Dose calculation was performed with AAA v.11 (1.0mm grid size); three focal spot size settings were tested: 0mm, 0.5mm, and 1.5mm. For each plan, three calculated doses (corresponding to each focal spot size setting) were compared to measured film dose using quantitative methods [Gamma Analysis(1%,1mm,10% threshold criteria)] and qualitative methods (visual dose profile comparison). Film calibration and analysis were performed using in-house calibration methods and software package.

RESULTS: Gamma(1%,1mm) analysis passing rate results [mean(st.dev){%}] were as follows. For DCA plans: 98.74(0.54)-[0mm Focal Spot Size]; 98.24(1.26)-[0.5mm Focal Spot Size]; 95.42(2.29)-[1.5mm Focal Spot Size]. For VMAT plans: 98.75(0.54)-[0mm Focal Spot Size]; 98.89(0.73)-[0.5mm Focal Spot Size]; 97.43(1.30)-[1.5mm Focal Spot Size]. The majority of failing points (Gamma value>1.0) were found to be within the high dose region for all Focal Spot Size calculation models. Visual inspection of the dose profile, showed that the 1.5mm Focal Spot size calculation exhibited blurring in the high dose region (defined as >85% of the peak dose), resulting in a more gradual shoulder of the dose profile relative to measurements.

CONCLUSION: The dose calculation accuracy of DCA and VMAT plans is paramount for SRS treatment planning. Our results indicate similar behavior of the AAA model with focal spot sizes of 0mm and 0.5mm, while 1.5mm focal spot size tends to result in blurring of the high dose region. Henry Ford Health System has research agreements with Varian and Philips.